Armed Forces Radiobiology Research Institute (AFRRI)
Humanetics entered into a Master Cooperative Research and Development Agreement (CRADA) with the Uniformed Services University of the Health Sciences (USU) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). The Congressionally-chartered USU is a fully-accredited graduate-education university operated by the Department of Defense (DoD) and is located in Bethesda, Maryland. HJF, located in Rockville, Maryland, is a private, not-for-profit organization chartered by Congress to support medical education and research at USU and throughout the military medical community.
Under the Master CRADA, Humanetics collaborated with Dr. Michael Landauer (now retired) at AFRRI to test and validate the efficacy of BIO 300 as a medical radiation countermeasure. Dr. Landauer is one of the original scientists to discover BIO 300's protective effects. He is a world leader in radiation injury and development of models that can lead to safe and effective drugs for use by the military, first responders and civilians.
To learn more about the Armed Forces Radiobiology Research Institute (AFRRI), click here.
University of Maryland School of Medicine
Humanetics has a strong collaboration with researchers at the University of Maryland, School of Medicine within its Division of Translational Radiation Sciences. The Radiation Oncology Research Laboratory Principal investigators research includes studying the biological processes involved in cellular DNA damage and repair responses, understanding the abnormal signaling pathways in cancer cells, and the evaluation of therapeutics. Each of these areas of research considerably accelerates the nonclinical work translation to the clinic as evidenced by the translational research initiatives launched in the Department. Humanetics has performed work for BARDA, NCI and NIAID with researchers at the University of Maryland. For more information, click here.
National Cancer Institute (NCI)
It is the mission of NCI to address research and training needs for the cause, diagnosis and treatment of cancer. NCI has been a key funding source for Humanetics’ preclinical and clinical studies for BIO 300 in the areas of lung and prostate cancer. NCI is intensely interested in developing both radioprotectants and radiosensitizers to improve the treatment of solid tumors. Humanetics has been working with NCI under various grants and contracts since 2012. To learn more about NCI, click here.
Biomedical Advanced Research and Development Authority (BARDA)
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. In 2011, Humanetics received a significant contract from BARDA to collaboratively develop BIO 300 for protection of the pulmonary system resulting from exposure to radiation. To learn more about BARDA, click here.
National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. NIAID is one of the 27 Institutes and Centers of the National Institutes of Health (NIH). Humanetics was awarded a small business innovation research grant from NIAID in 2016 to further develop BIO 300 to protect lung function after exposure to radiation. For more information about NIAID, click here.